Barbara Freischem

C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom.

Quethera Ltd. develops treatment for eye diseases. It focuses on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. The company was founded by Peter Stuart Widdowson and Keith Robert Graham Martin in 2013 and is headquartered in Cambridge, the United Kingdom.

The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members.

Ikarovec Ltd. provides human health care services. The company is headquartered in Canterbury, the United Kingdom.

Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.

Part of GSK Plc, Smithkline Beecham Holdings Corp. produces and distributes pharmaceutical products and dental healthcare products. The company is based in Wilmington, DE.

The Alliance for Advanced Therapies’ mission is to improve the legislative, business and science climate for advanced therapies innovation in Europe. In order to do so, AAT promotes the interests of its members and the advanced therapies sector in Europe. AAT coordinates input to, and exchanges information with relevant European authorities. The Alliance also increases awareness of the sector among all relevant stakeholders, with a special focus on investors. Furthermore, AAT promotes increased funding for the sector from public and private sources.

Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA.

Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest.

Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Sutura Therapeutics Ltd. is a British biopharmaceutical company that is advancing biomolecular medicine through its Peptigo technology platform. The company is based in Macclesfield, UK. Sutura's team is made up of skilled and passionate professionals who bring a unique perspective to the table. The company was founded in 2020, and Edwin J. Wagena has been the CEO of the company since 2021.

OncoDNA SA develops and provides diagnostic and analytical tools for cancer treatment. The firm offers treatment options, integrated biological review, monitoring, pathology and DNA sequencing. The company was founded by Jean-Pol Detiffe on November 29, 2012 and is headquartered in Gosselies, Belgium.

Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France.

Part of TiGenix NV, Tigenix SAU is a Spanish company that collects all the research and development of health, agri-food and industrial products from its partners. The company is based in Tres Cantos, Spain. The company has been driving biotechnology in Spain since 1999 and have more than 300 associated companies, startups, and entities. The group Zendal, a 100%% Spanish biopharmaceutical group, includes seven companies focused on manufacturing and commercializing high-value biotechnology products. Tigenix SAU is a member of AseBio, and the membership fees vary depending on the type of entity and the company's age, annual turnover, and equity. The company offers discounts and economic advantages to their members. The AseBio Investor Day is an investment forum that aims to connect the Spanish biotechnology industry with investors.

eureKING SA is a special purpose acquisition company, which engages in acquiring one or more companies or operating businesses, through a merger, capital stock exchange, share purchase, asset acquisition, reorganization or similar transaction. It focuses on the completion of an initial business combination with one or several target businesses and companies with principal operations in the biomanufacturing sector. The company was founded by Michael Kloss, Hubert Olivier, Gerard Le Fur, Christophe Jean, Alexandre Mouradian, and Rodolphe Besserve and is headquartered in Paris, France.

Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.

Pierre Fabre Group manufactures cosmetics and skincare products. The private company is based in Paris, France. The CEO of the French company is Eric Ducournau.

Keosys SAS specializes in imaging and communication systems for nuclear medicine and radiology. It engages in medical imaging, telecommunication and information technology services. The firm develops products and services for medical diagnosis and clinical trials. The company was founded in 2001 and is headquartered in Saint-Herblain, France.

Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ.

Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.

Back to Basics, Inc. is an American company that is currently open for business. The private company prioritizes the safety of their staff and their families, especially those who are in high-risk groups. Customers are required to wear masks when entering the store.

Ipsen Pharma SA manufactures and distributes pharmaceutical products. It supplies products to the therapeutic areas such as oncology, endocrinology, and neuromuscular disorders. The firm also develops drugs for gastroenterology, cognitive disorders, and cardiovascular diseases. Ipsen Pharma is headquartered in Sant Feliu de Llobregat, Spain.

Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.